Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

B-cell acute lymphoblastic leukemia with high mutation burden presenting in a child with constitutional mismatch repair deficiency.

Blood advances·2019
Same author

Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed Neuroblastoma.

Journal of pediatric hematology/oncology·2015
See all related articles

Related Experiment Video

Updated: Apr 22, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.8K

Langerhans cell histiocytosis.

Nanette Grana1

  • 1All Children's Hospital, St Petersburg, FL 33701, USA. ngrana1@jhmi.org.

Cancer Control : Journal of the Moffitt Cancer Center
|October 14, 2014
PubMed
Summary

Langerhans cell histiocytosis (LCH) is a rare disorder affecting children and adults, with distinct prognoses based on risk. Advances in understanding genetic mutations and targeted therapies are improving outcomes, especially for pediatric patients.

Area of Science:

  • Oncology
  • Genetics
  • Pediatrics

Background:

  • Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder with unknown origins.
  • It presents variably, from localized skin/bone disease to life-threatening multisystem conditions, more frequent in pediatric populations.
  • Activating somatic mutations in BRAF V600E and MAP2K1 genes are found in ~75% of patients, suggesting a neoplastic origin.

Purpose of the Study:

  • To review current literature on the diagnosis, management, and prognosis of Langerhans cell histiocytosis.
  • To emphasize contemporary clinical practice in LCH patient care.

Main Methods:

  • Literature survey on Langerhans cell histiocytosis.
  • Data collection, analysis, and discussion focused on current clinical practices.

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

8.5K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

10.6K

Related Experiment Videos

Last Updated: Apr 22, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.8K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

8.5K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

10.6K

Main Results:

  • Pediatric LCH often presents aggressively, requiring systemic chemotherapy, while adult LCH typically involves limited skin/bone disease with high survival rates.
  • Low-risk LCH shows excellent prognosis (~99% survival), whereas high-risk LCH has ~80% survival.
  • Smoking cessation aids pulmonary LCH, and BRAF inhibitor targeted therapy shows promise.

Conclusions:

  • Understanding of LCH has significantly advanced in the past two decades.
  • Current treatments effectively manage LCH in most patients.
  • Novel driver mutations and targeted therapies offer potential for improved outcomes and reduced adverse events, particularly for pediatric and adolescent patients.